Chapter 21 : Fluoroquinolones in Intensive Care Unit Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Fluoroquinolones in Intensive Care Unit Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap21-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap21-2.gif


Patients with life-threatening severe community-acquired infections or infections that compromise vital organ functions are often treated in intensive care units (ICUs). The ICU is the "meeting point" for severe community-acquired infections and nosocomial infections. Among resistant gram-negative pathogens, the most common sources in the ICU are infections of the respiratory tract and urinary tract. A recent article found an association in an ICU setting between the amount of intravenous fluoroquinolones prescribed and the incidence of endemic infection with and strains resistant to fluoroquinolones. The chapter discusses pharmacokinetic factors that are likely to differ in ICU patients. Fluoroquinolones have been used frequently to treat nosocomial infections in the ICU because of their pronounced activity against resistant gram-negative bacteria, their lack of association with colitis, and their lack of promo¬tion of vancomycin-resistant enterococci. Among the fluoroquinolones, clinafloxacin was most active, whereas ciprofloxacin and fleroxacin were the least active. At present, the newer fluoroquinolones (levofloxacin, moxifloxacin, and gatifloxacin) with their improved activity against gram-positive pathogens do not seem to add much to present therapeutic options for nosocomial infections. However, in vitro data of some of the more advanced fluoroquinolones, like gemifloxacin, garenoxacin and clinafloxacin, might make them useful alternatives for treatment of nosoco­mial gram-positive infections in ICUs.

Citation: Rubinstein E. 2003. Fluoroquinolones in Intensive Care Unit Infections, p 337-342. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch21
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Alonso, R.,, T. Pelaez,, M. J . Gonzalez-Abad,, L. Alcala,, P. Munoz,, M. Rodriguez-Creixems,, and E. Bouza. 2001. In vitro activity of new quinolones against Clostridium difficile. J. Antimicrob. Chemother. 47:195197.
2. Carmeli, Y.,, N. Troillet,, G. M. Eliopoulos,, and M. H. Samore. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:13791382.
3. Cheong, H. J.,, C. W. Yoo,, J. W. Sohn,, W. J. Kim,, M. J. Kim,, and S. C. Park. 2001. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin. Infect. Dis. 33:4853.
4. Civetta, J. M.,, R. W. Taylor,, and R. R. Kirby (ed.). 1997. Critical Care , 3rd ed. Lippincott-Raven, Philadelphia, Pa.
5. Coronado, V. G.,, J. R. Edwards,, D. H. Culver,, and R. P. Gaynes, for the National Nosocomial Infections Surveillance (NNIS) System. 1995. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect. Control. Hosp. Epidemiol. 16:71.
6. Finkelstein, R.,, G. Rabino,, I. Kassis,, and I. Macmid. 2000. Device-associated, device-day infection rates in an Israeli adult general intensive care unit. J. Hosp. Infect. 44:200205.
6a. Fraisse, A.,, C. Croix,, D. Maniere,, and P. Pfitzenmeyer. 1999. Diarrhee a Clostridium difficile chez le sujet tres age. Particularites cliniques et evolutives de 21 cases. [Clostridium difficile diarrhea in the very old. Clinical features and course in 21 cases] Presse. Med. 28:17481752.
7. Fung-Tome, J.-C.,, B. Minassian,, B. Kolek,, E. Huczko,, L. Aleksunes,, T. Stickle,, T. Washo,, E. Gradelski,, L. Valera,, and D. P. Bonner. 2000. Antibacterial spectrum of a novel desfluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44:33513356.
8. Geddes, A.,, M. Thaler,, S. Schonwald,, M. Harkonen,, F. Jacobs,, and I. Nowotny. 1999. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. J. Antimicrob. Chemother. 44:799810.
9. Gilman, A. G.,, L. S. Goodman,, T. W. Rail, et al. (ed.). 2000. The Pharmacologic Basis of Therapeutics. Macmillan Publishing Co., New York, N.Y.
10. Hanberger, H.,, J. A. Garcia-Rodriguez,, M. Gobernado,, H. Goossens,, L. E. Nilsson,, and M. J. Struelens. 1999. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 281:6771.
11. Hansen, M.,, M. R. Poulsen,, D. K. Bendixen,, and F. Hartmann-Andersen. 1988. Incidence of sinusitis in patients with nasotracheal intubation. Br. J. Anaesth. 61:231.
12. Heyland, D. K.,, D. J. Cook,, L. Griffith,, S. P. Keenan,, and C. Bruin-Buisson. 1999. The attributable morbidity and mortality of ventilator-associated pneumonia in critically ill patients. Am. J. Respir. Crit. Care Med. 159:12491256.
13. Hsueh, P.-R.,, L. J. Teng,, P. C. Yang,, Y. C. Chen,, S. W. Ho,, and K. T. Luh. 1998. Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J. Clin. Microbiol. 36:13471351.
14. Jamal, W.-Y.,, K. El-Din,, V. O. Rotimi,, and T. D. Chugh. 1999. An analysis of hospital-acquired bacteraemia in intensive care unit patients in a university hospital in Kuwait. J. Hosp. Infect. 43:4956.
15. Kerr, K.-G.,, H. T. Armitage,, and P. H. McWhinney. 1999. Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy. Support. Care Cancer 7:2830.
16. Koleff, M.,, and M. Niederman. 2001. Antimicrobial resistance in the ICU. The time for action is now. Crit. Care Med. 29(Suppl.):N63.
17. Kollef, M. H.,, G. Sherman,, S. Ward,, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462474.
18. Kollef, M.H.,, J. Vlasnik,, L. Sharpless,, C. Pasque,, D. Murphy,, and V. J. Fraser. 1997. Scheduled rotation of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia due to antibiotic-resistant gram-negative bacteria. Am. J. Respir. Crit. Care Med. 156:10401048.
19. Kollef, M.-H.,, J. Vlasnik,, L. Sharpless,, C. Pasque,, D. Murphy,, and V. Fraser. 1997. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156:10401048.
20. Koleff, M. H.,, S. Ward,, G. Sherman,, D. Prentice,, R. Schaiff,, W. Huey,, and V. J. Fraser. 2000. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit. Care Med. 28:34563464.
21. Krumpe, P.-E.,, S. Cohn,, J. Garreltes,, J. Ramirez,, H. Coulter,, D. Haverstock,, and R. Echols. 1999. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. J. Antimicrob. Chemother. 43(Suppl. A):117128.
22. Legras, A.,, D. Malvy,, A. I. Quinioux,, D. Villers,, G. Bouachour,, R. Robert,, and R. Thomas. 1998. Nosocomial infections: prospective survey of incidence in five French intensive care units. Intensive Care Med. 24:10401046.
23. McDonald, L. C.,, F. J. Chen,, H. J. Lo,, H. C. Yin,, P. L. Lu,, C. H. Huang,, P. Chen,, T. L. Lauderdale,, and M. Ho. 2001. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinctive selective pressures. Antimicrob. Agents Chemother. 45:30843091.
24. MacGowan, A. P.,, C. A. Rogers,, A. Holt,, M. Wooton,, and K. E. Bowker. 2001. Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection. Antimicrob. Agents Chemother. 45:29162921.
25. Mermel, L. A.,, B. M. R. J. Farr,, Sheretz,, I. I. Raad,, N. O'Grady,, J. A. Harris,, and D. E. Craven. 2001. Guidelines for the management of intravascular related infections. Clin. Infect. Dis. 32:12491272.
26. Paterson, D. L.,, L. Mulazimoglu,, J. M. Casssellas,, W. C. Ko,, H. Goossens,, A. Von-Gottberg,, S. Mohapatra,, G. N. Trenholme,, K. P. Klugman,, J. G. McCormack,, and V. L. Yu. 2000. Epidemiology of ciprofloxacin resistance to extendedspectrum beta-lactamase production I Klebsiella pneumoniae isolates causing bactermia. Clin. Infect. Dis. 30:473478.
27. Pieroni, P.,, J. Goodfellow,, L. Reesor,, M. Louie,, and A. E. Simor. 1997. Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin. J. Antimicrob. Chemother. 39:419422.
28. Puzniak, L. A.,, J. Mayfield,, T. Leet,, M. Kollef,, and L. M. Mundy. 2001. Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit. Clin. Infect. Dis. 33:151157.
29. Schentag, J. J. 1999. Antimicrobial action and pharmacokinetics/ pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J. Chemother. 11:426439.
30. Siegrist, H. H,, M. C. Nepa,, and A. Jacquet. 1999. Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: a multicentre study. J. Antimicrob. Chemother. 43(Suppl. C):5154.
31. Solomkin, J. S. 1996. Antimicrobial resistance: an overview. NewHoriz. 4:319320.
32. Traynor, A. M.,, A. N. Nafziger,, and J. S. Bertino. 1995. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob. Agents Chemother. 39:545551.
33. Villers, D.,, E. Espaze,, M. F. Coste-Burel,, F. Giauffret,, E. Ninin,, F. Nicolas,, and H. Richet. 1998. Nosocomial Acinetobacter baumanii infections: microbiological and clinical epidemiology. Ann. Intern. Med. 129:182189.
34. Vincent, J. L.,, D. J. Bihari,, P. M. Suter,, H. A. Braining,, J. White,, M. H. Nicolas-Chanoin,, M. Wolff,, R. C. Spencer,, and M. Hemmer. 1995. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639644.
35. Wisplinghoff, H.,, R. R. Reinert,, O. Cornely,, and H. Seifert. 1999. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J. Clin. Microbiol. 37:18761880.
36. Wright, D.H.,, L. B. Horde,, M. Peterson,, A. D. Hoang,, and J. C. Rotscafer. 1998. Program and Abstracts of the 98th General Meeting of the American Society for Microbiology, 1998 , abstr. A-86, p. 53. American Society for Microbiology, Washington, D.C.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error